Li-Shan Tan1, Xiao-Yan Huang1, Yun-Feng Wang2, Yan Jia1, Qi-Lin Pang3, Wei-Xing Zhang3, Zu-Ying Xiong1, Lei Huang3, Jin-Xiu Li4. 1. Department of Nephrology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center Shenzhen, China. 2. School of Public Health, Capital Medical University Beijing, China. 3. Department of Critical Care Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center Shenzhen, China. 4. Department of Critical Care Medicine, The Third People's Hospital of Shenzhen Shenzhen, China.
Abstract
BACKGROUND: Acute kidney injury (AKI) was found in some patients with COVID-19 pneumonia and accompanied with poor outcomes. The objective of this study was to investigate the association of AKI with clinical outcomes in COVID-19 patients. METHODS: In this cohort study, we reviewed electronic medical data from patients with COVID-19 in Shenzhen from January 11 to February 19, 2020. Clinical features and clinical outcomes in COVID-19 patients with and without AKI were analyzed. Further, we evaluated the association between AKI development and clinical outcomes. RESULTS: In this study, 9.6% patients developed AKI during hospitalization. Those with AKI presented older age, severer pneumonia, more comorbidity and lower lymphocyte count. Totally, more patients (77.5%) had primary composite outcomes (intensive care unit (ICU) admission, use of high-flow nasal cannula (HFNC) and mechanical ventilation) in AKI group compared to non-AKI group (2.9%) during the observation period. The median length of stay (LOS) and ICU stay were longer among those with AKI. After adjusted for related covariates, AKI development was independently correlated with LOS (β (95% CI): 9.16 (3.87-14.46)), rather than primary outcomes (HR (95% CI): 1.34 (0.56-3.21)) in COVID-19 patients. CONCLUSIONS: The development of AKI was not one of the reasons for ICU admission, use of HFNC and mechanical ventilation, but a kind of manifestation of severe illness in COVID-19 hospitalized patients. AJTR
BACKGROUND:Acute kidney injury (AKI) was found in some patients with COVID-19 pneumonia and accompanied with poor outcomes. The objective of this study was to investigate the association of AKI with clinical outcomes in COVID-19patients. METHODS: In this cohort study, we reviewed electronic medical data from patients with COVID-19 in Shenzhen from January 11 to February 19, 2020. Clinical features and clinical outcomes in COVID-19patients with and without AKI were analyzed. Further, we evaluated the association between AKI development and clinical outcomes. RESULTS: In this study, 9.6% patients developed AKI during hospitalization. Those with AKI presented older age, severer pneumonia, more comorbidity and lower lymphocyte count. Totally, more patients (77.5%) had primary composite outcomes (intensive care unit (ICU) admission, use of high-flow nasal cannula (HFNC) and mechanical ventilation) in AKI group compared to non-AKI group (2.9%) during the observation period. The median length of stay (LOS) and ICU stay were longer among those with AKI. After adjusted for related covariates, AKI development was independently correlated with LOS (β (95% CI): 9.16 (3.87-14.46)), rather than primary outcomes (HR (95% CI): 1.34 (0.56-3.21)) in COVID-19patients. CONCLUSIONS: The development of AKI was not one of the reasons for ICU admission, use of HFNC and mechanical ventilation, but a kind of manifestation of severe illness in COVID-19 hospitalized patients. AJTR
Authors: Seung Seok Han; Shin Young Ahn; Jiwon Ryu; Seon Ha Baek; Ho Jun Chin; Ki Young Na; Dong-Wan Chae; Sejoong Kim Journal: BMC Nephrol Date: 2014-06-18 Impact factor: 2.388
Authors: Jamie S Hirsch; Jia H Ng; Daniel W Ross; Purva Sharma; Hitesh H Shah; Richard L Barnett; Azzour D Hazzan; Steven Fishbane; Kenar D Jhaveri Journal: Kidney Int Date: 2020-05-16 Impact factor: 10.612
Authors: Lauren A Henderson; Scott W Canna; Grant S Schulert; Stefano Volpi; Pui Y Lee; Kate F Kernan; Roberto Caricchio; Shawn Mahmud; Melissa M Hazen; Olha Halyabar; Kacie J Hoyt; Joseph Han; Alexei A Grom; Marco Gattorno; Angelo Ravelli; Fabrizio De Benedetti; Edward M Behrens; Randy Q Cron; Peter A Nigrovic Journal: Arthritis Rheumatol Date: 2020-05-10 Impact factor: 15.483